Cargando…

MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker

Multiple targeted therapy for advanced clear-cell renal cell carcinoma (RCC) has substantially improved patient outcome, but complete remission is uncommon and many tumors eventually develop resistance. Mechanistic, preclinical, and early clinical data highlight c-Met / hepatocyte growth factor rece...

Descripción completa

Detalles Bibliográficos
Autores principales:	Macher-Goeppinger, Stephan, Keith, Martina, Endris, Volker, Penzel, Roland, Tagscherer, Katrin E., Pahernik, Sascha, Hohenfellner, Markus, Gardner, Humphrey, Grüllich, Carsten, Schirmacher, Peter, Roth, Wilfried
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352033/ https://www.ncbi.nlm.nih.gov/pubmed/27894094 http://dx.doi.org/10.18632/oncotarget.13540

Ejemplares similares

Prognostic relevance of androgen receptor expression in renal cell carcinomas
por: Foersch, Sebastian, et al.
Publicado: (2017)

Expression and Functional Characterization of the BNIP3 Protein in Renal Cell Carcinomas
por: Macher-Goeppinger, Stephan, et al.
Publicado: (2017)

The ribosomal protein S6 in renal cell carcinoma: functional relevance and potential as biomarker
por: Knoll, Maximilian, et al.
Publicado: (2015)

Uncoupling of PUMA Expression and Apoptosis Contributes to Functional Heterogeneity in Renal Cell Carcinoma — Prognostic and Translational Implications()
por: Zhou, Xiaoguang, et al.
Publicado: (2015)

Lamin-B1 is a senescence-associated biomarker in clear-cell renal cell carcinoma
por: Radspieler, Melissa Marie, et al.
Publicado: (2019)

Prognostic and Predictive Value of Tumor-infiltrating Leukocytes and of Immune Checkpoint Molecules PD1 and PDL1 in Clear Cell Renal Cell Carcinoma
por: Stenzel, Philipp J., et al.
Publicado: (2019)

Harnessing the p53-PUMA Axis to Overcome DNA Damage Resistance in Renal Cell Carcinoma()
por: Zhou, Xiaoguang, et al.
Publicado: (2014)

MicroRNA-210 induces apoptosis in colorectal cancer via induction of reactive oxygen
por: Tagscherer, Katrin E., et al.
Publicado: (2016)

Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy
por: Dietz, Steffen, et al.
Publicado: (2017)

Nivolumab Reduces PD1 Expression and Alters Density and Proliferation of Tumor Infiltrating Immune Cells in a Tissue Slice Culture Model of Renal Cell Carcinoma
por: Stenzel, Philipp J., et al.
Publicado: (2021)

Prospective single center trial of next-generation sequencing analysis in metastatic renal cell cancer: the MORE-TRIAL
por: Dieffenbacher, Svenja, et al.
Publicado: (2018)

The soluble Decoy Receptor 3 is regulated by a PI3K-dependent mechanism and promotes migration and invasion in renal cell carcinoma
por: Weissinger, Daniel, et al.
Publicado: (2013)

Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma
por: Wagener, Nina, et al.
Publicado: (2010)

Survival outcomes of patients with germ cell tumors treated with high-dose chemotherapy for refractory or relapsing disease
por: Zschäbitz, Stefanie, et al.
Publicado: (2018)

Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneity
por: Hoefflin, Rouven, et al.
Publicado: (2016)

Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German Centers
por: Zschäbitz, Stefanie, et al.
Publicado: (2017)

Assessment of PI3K/mTOR/AKT Pathway Elements to Serve as Biomarkers and Therapeutic Targets in Penile Cancer
por: Thomas, Anita, et al.
Publicado: (2021)

Mutations in BRCA2 and taxane resistance in prostate cancer
por: Nientiedt, Cathleen, et al.
Publicado: (2017)

Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate
por: Apostolidis, Leonidas, et al.
Publicado: (2019)

Prognostic Significance and Functional Role of CEP57 in Prostate Cancer()
por: Mang, Josef, et al.
Publicado: (2015)

Microsatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a population‐based study
por: Alwers, Elizabeth, et al.
Publicado: (2020)

Genomic features of renal cell carcinoma with venous tumor thrombus
por: Warsow, Gregor, et al.
Publicado: (2018)

Value of c-MET and Associated Signaling Elements for Predicting Outcomes and Targeted Therapy in Penile Cancer
por: Thomas, Anita, et al.
Publicado: (2022)

MET Inhibition in Clear Cell Renal Cell Carcinoma
por: Xie, Zuoquan, et al.
Publicado: (2016)

The BRCA2 mutation status shapes the immune phenotype of prostate cancer
por: Jenzer, Maximilian, et al.
Publicado: (2019)

Ioncopy: an R Shiny app to call copy number alterations in targeted NGS data
por: Budczies, Jan, et al.
Publicado: (2018)

BAP1 and PTEN mutations shape the immunological landscape of clear cell renal cell carcinoma and reveal the intertumoral heterogeneity of T cell suppression: a proof-of-concept study
por: Friedhoff, Jana, et al.
Publicado: (2022)

Paraganglioma of the Seminal Vesicle Case Report and Review of the Literature
por: Tosev, Georgi, et al.
Publicado: (2016)

Genetic changes of non-small cell lung cancer under neoadjuvant therapy
por: Warth, Arne, et al.
Publicado: (2016)

MET Expression in Primary and Metastatic Clear Cell Renal Cell Carcinoma: Implications of Correlative Biomarker Assessment to MET Pathway Inhibitors
por: Shuch, Brian, et al.
Publicado: (2015)

Prognostic value of MET, cyclin D1 and MET gene copy number in non-small cell lung cancer
por: Sun, Wenze, et al.
Publicado: (2013)

HMGB1: The metabolic weapon in the arsenal of NK cells
por: Cerwenka, Adelheid, et al.
Publicado: (2016)

Endogenous BTG2 expression stimulates migration of bladder cancer cells and correlates with poor clinical prognosis for bladder cancer patients
por: Wagener, N, et al.
Publicado: (2013)

Ex vivo tissue slice culture system to measure drug-response rates of hepatic metastatic colorectal cancer
por: Martin, Steve Z., et al.
Publicado: (2019)

c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma
por: Kim, Ha-Jeong, et al.
Publicado: (2016)

Next-generation sequencing facilitates detection of the classic E13-A20 EML4-ALK fusion in an ALK-FISH/IHC inconclusive biopsy of a stage IV lung cancer patient: a case report
por: Volckmar, Anna-Lena, et al.
Publicado: (2016)

Comprehensive analysis of somatic copy number alterations in clear cell renal cell carcinoma
por: Tsuyukubo, Takashi, et al.
Publicado: (2020)

Significance of the Intraoperative Methylene Blue Test for Postoperative Evaluation of the Vesicourethral Anastomosis
por: Nyarangi-Dix, J. N., et al.
Publicado: (2012)

EZH2 Depletion Blocks the Proliferation of Colon Cancer Cells
por: Fussbroich, Bettina, et al.
Publicado: (2011)

The study on copy number alteration of clear cell renal cancer in Chinese population
por: Zhang, Ning, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ik7hc28bbmg3ehkkrj8i5vtt66